Scholar Rock Holding Corp (NASDAQ:SRRK)
| Market Cap | 5.05B+36.0% |
| Revenue (ttm) | 0 |
| Net Income | -408.59M-29.4% |
| EPS | -3.31-11.1% |
| Shares Out | 121.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,206,859 |
| Open | 41.58 |
| Previous Close | 41.96 |
| Day's Range | 40.76 - 41.88 |
| 52-Week Range | 27.07 - 61.76 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 71.30(+71.85%) |
| Earnings Date | Nov 10, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SRRK stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SRRK holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SRRK's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SRRK Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SRRK patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SRRK from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SRRK
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $166.51M |
| IWMiShares Russell 2000 ETF | $117.61M |
| XBIState Street SPDR S&P Biotech ETF | $81.52M |
| VBVanguard Morningstar Small-Cap ETF | $59.53M |
| VXFVanguard Extended Market ETF | $55.84M |
| IWOiShares Russell 2000 Growth ETF | $41.26M |
Estimated from each fund’s disclosed top holdings × AUM
SRRK Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SRRK’s recent data — informational, not investment advice